Autism and Epilepsy Initiative

A quarter of all patients with autism have epilepsy.  

 

In individuals with autism, epilepsy is often difficult to control and severely affects their quality of life.  FACES has supported the creation of a clinical and genetic data repository of people with autism and epilepsy, with the aim of identifying biomarkers for drug responsiveness.  Epilepsy in autism is associated with lower cognitive ability and more severe behavioral symptoms.  

  • We are also partnering with the Simons Foundation to identify quantitative MRI abnormalities in the brains of people with autism that are potential biomarkers for seizure risk and responsiveness to medications.  
  • Another study in collaboration with Richard Tsien, PhD, Director of the NYU Druckenmiller is investigating human brain tissue and animal models of autism to understand the molecular mechanisms that contribute to both epilepsy and autism.